Imexpharm

Imexpharm Receivables

The Accounts Receivable of Imexpharm (IMP.VN) as of Oct 27, 2026 is 323.28 B VND. In the previous year, Accounts Receivable was 334.75 B VND — a change of -3.43% (lower).

Receivables

323.28 BVND

YoY

-3.43%

Last updated:

Accounts Receivable of Imexpharm is 2025 323.28 B VND. Accounts Receivable of Imexpharm was 2024 334.75 B VND. It decreases by -3.43% lower compared to the previous year.

The Imexpharm Receivables history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Receivables
Date
Receivables
Jan 1, 2018
172.99 B VND
Jan 1, 2019
239.81 B VND
Jan 1, 2020
317.99 B VND
Jan 1, 2021
234.56 B VND
Jan 1, 2022
217.38 B VND
Jan 1, 2023
254.06 B VND
Jan 1, 2024
334.75 B VND
Jan 1, 2025
323.28 B VND
The Imexpharm Receivables history
YEARReceivablesYoY
323.28 BVND-3.43%
334.75 BVND+31.76%
254.06 BVND+16.87%
217.38 BVND-7.32%
234.56 BVND-26.23%
317.99 BVND+32.60%
239.81 BVND+38.62%
172.99 BVND-20.67%
218.06 BVND+3.33%
211.04 BVND-1.47%
214.18 BVND+7.56%
199.13 BVND—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Imexpharm Stock analysis

What does Imexpharm do? Imexpharm Corp manufactures and trades pharmaceuticals, medicinal chemicals, and botanical products, including antiseptics, traditional medicine, medical equipment, cosmetics, and supplemental food and drinks. The company provides packaging and warehousing services specifically for pharmaceutical storage. It also cultivates medicinal herbs. Imexpharm Corp serves the pharmaceutical industry and healthcare sector through its manufacturing, import, export, and trade operations, targeting businesses requiring medicinal products and services. The company's revenue streams include the sale of manufactured pharmaceuticals, imported and exported goods, and services such as packaging and warehousing. Its customers are businesses in the healthcare sector, including distributors and retailers of pharmaceuticals, medical equipment, and related products. The firm's operations span manufacturing, import, export, and trade, with additional services supporting the pharmaceutical supply chain. Imexpharm Corp's product portfolio covers a wide range of medicinal and health-related items, from antiseptics to supplemental food and drinks. The company's involvement in medicinal herb cultivation supports its production of traditional medicine and herbal-based products. This vertical integration enhances its ability to supply comprehensive solutions to healthcare businesses. Imexpharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imexpharm stock

Accounts Receivable of Imexpharm is 323.28 B VND in 2025.

Accounts Receivable of Imexpharm changed from 334.75 B VND to 323.28 B VND, representing a -3.43% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Accounts Receivable Imexpharm since 2006 – with annual values, charts, and detailed analysis.

Receivables represent money owed to the company by customers for goods or services delivered. High receivables relative to revenue may indicate collection issues.

Accounts Receivable's VND is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Receivable's Imexpharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Imexpharm

All Key Metrics — Imexpharm